REPLICEL LIFE SCIENCES INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0428 USD | +4.99% |
|
-.--% | -4.89% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Companyâs cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.
Calendar
2024-04-29
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -4.89% | 2.78M | |
| -2.25% | 103B | |
| +1.86% | 96.56B | |
| +1.37% | 22.61B | |
| -17.99% | 21.18B | |
| -4.97% | 19.07B | |
| -41.75% | 16.53B | |
| -24.27% | 14.46B | |
| +1.82% | 13.25B | |
| +22.55% | 11.1B |
- Stock Market
- Equities
- REPCF Stock
- News RepliCel Life Sciences Inc.
- RepliCel Brief: CEO Says Targets for 2021 Include "Dermal Injector Commercial Launch, New Partnerships, New Innovation initiatives, and Launch of More Clinical Testing"
